Physician profile
Milena Vukelic
NPI 1013323641
$3,128.46
in general payments reported to CMS, 2019-2025
23 companies · $2,243 in 2025
The $2,243 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $91.68 · 2021: $348 · 2024: $446 · 2025: $2,243.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,589 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,588.82 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $737.92 | 2021-2025 | Krystexxa, Tavneos, Evenity |
| Abbvie INC. | $472.24 | 2020-2025 | |
| Mallinckrodt Hospital Products INC. | $262.73 | 2024-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $218.66 | 2025 | |
| Genzyme Corporation | $210.92 | 2024-2025 | |
| Pfizer INC. | $198.56 | 2020-2025 | |
| Ucb, INC. | $159.38 | 2021-2025 | Bimzelx |
| Sanofi-Aventis U.S. LLC | $153.13 | 2025 | |
| Aurinia Pharma U.S., INC. | $148.64 | 2024-2025 | Lupkynis |
| Glaxosmithkline, LLC. | $94.13 | 2021-2025 | Benlysta |
| Kyowa Kirin, INC. | $75.07 | 2025 | |
| Lilly USA, LLC | $74.68 | 2021 | |
| Alexion Pharmaceuticals, INC. | $45.73 | 2025 | Strensiq |
| Rhythm Pharmaceuticals, INC. | $40.69 | 2025 | Imcivree |
| Janssen Scientific Affairs, LLC | $40.12 | 2025 | Tremfya |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $39.90 | 2025 | Sotyktu |
| Boston Scientific Corporation | $34.78 | 2025 | Watchman Flx |
| Vanda Pharmaceuticals INC. | $23.66 | 2025 | Ponvory |
| Novo Nordisk INC | $22.64 | 2025 | Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $21.43 | 2025 | Purified Cortrophin Gel |
| Neurocrine Biosciences, INC. | $18.61 | 2025 | |
| Merz Pharmaceuticals, LLC | $18.09 | 2025 | Inbrija, Ampyra, Xeomin |
| Xeris Pharmaceuticals, INC. | $16.75 | 2025 | Recorlev |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Milena Vukelic listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.